Laura Berezin is a member of Cooley's business department leadership team. She focuses her practice on corporate securities, M&A and complex corporate finance transactions, with a particular emphasis on representing clients in the life sciences industry. She represents public and private corporations, investment banks, venture capital funds, and financial institutions both in the United States and Europe in a variety of capital market transactions, including public offerings, private placements, PIPES and 144A transactions. Laura has extensive experience in representing life science companies in spin-outs and other domestic and cross-border M&A. Her general corporate practice includes formation and financing activities, securities compliance, public company disclosure and corporate governance matters. She also has extensive experience in counseling publicly-traded life sciences companies and their boards of directors. Laura has also served as a member of BIO's Emerging Company Governing Board. 

Download full bio 


  • Kyverna Therapeutics Closes $85 Million Series B 

  • Five Prime Therapeutics Agrees to Sell to Amgen for $1.9 Billion 

  • Ovid - $75 Million IPO 

  • ALX Oncology – $186 Million IPO 

  • Vir Biotechnology - $143 Million IPO 

  • View all


  • University of Pennsylvania Law School
    JD, 1992

  • University of California, Berkeley
    BS, Phi Beta Kappa, with high honors

Admissions & Credentials


Rankings & Accolades

    Best Lawyers in America: Lawyer of the Year: California (2023)

    Best Lawyers: Lawyer of the Year – Securities Regulation (2021)

    Chambers USA: Life Sciences: Corporate/Commercial – California (2022)

    Best Lawyers in America: Biotechnology Law, Securities and Capital Markets Law and Securities Regulation

    Best Lawyers: Lawyer of the Year – Biotechnology Law 

    LMG Life Sciences Corporate Attorney of the Year (2018)

    Legal 500 US: Life Sciences, Capital Markets and M&A: Venture Capital and Emerging Companies

    PLC – Which Lawyer? Equity Capital Markets and Corporate Life Sciences

    Daily Journal: Top 25 Biotech Lawyers in California (2011)